The Plasma Fractionation market studied is anticipated to grow with a CAGR of nearly 8.76%, during the forecast period. Certain factors that are driving the market growth include growing use of immunoglobulins in various therapeutic areas, rising geriatric population coupled with rise in prevalence of rare diseases, and increasing number of plasma collection centers across the globe.
The rise in the elderly population has led to the rise in demand for plasma fractionation. According to the Centers for Diseases Control and Prevention, the number of adults unable (or very difficult) to walk a mile was found to be around 17.1 million in 2016. As per the revised World Population Prospects, by the United Nations, the number of people aged 60 or above is expected to grow greater than double by 2050, i.e. from 962 million in 2017 to 2.1 billion in 2050, globally. This age group is highly vulnerable to different types of age-related diseases that require various plasma protein therapeutics.
Moreover, the increasing prevalence of debilitating neurological diseases, rheumatoid arthritis, and osteoarthritis has been contributing to the increased percentage of the population with a need for advanced therapeutics.
Key Market Trends Albumin Shows Lucrative Growth Opportunity in the Global Plasma Fractionation Market
Human albumin (HA) is the most abundant circulating protein in the plasma of healthy individuals (3.5–5 g/dL). Albumin represents roughly 50% of the total protein content. HA is the main modulator of fluid distribution among the compartments of the body, providing approximately 70–80% of the total plasma oncotic pressure.
However, many other non-oncotic properties that are unrelated to the regulation of fluid compartmentalisation (and are mostly the result of the peculiar structure and conformation of the molecule) have been identified in the last two decades. Consequently, over the past decade, there has been an observed increment in the use of human albumin as a non-therapeutic material, specifically for commercial settings. A large number of biotech and biopharmaceutical firms are expected to develop recombinant versions of albumin to explore its potential in extending the half-life and stability to biologics and bio-similars. As of 2018, there were at least 15 products under clinical trial that involve the use of human albumin as an excipient (stabiliser and drug formulation).
In 2018, Grifols, one of the world’s top three producers of plasma-derived medicines, conducted and successfully concluded the experimental phase of AMBAR (Alzheimer Management By Albumin Replacement) clinical trial.
North America Dominates the Global Plasma Fractionation Market
In the North American region, the United States accounted for the largest market share due to the rising geriatric population and various associated diseases. The Alzheimer’s Association stated that around 5.8 million people in the United States are living with Alzheimer’s disease in 2018. This disease is the sixth leading cause of death in the United States and is more prevalent among people above 65 years of age, as approximately 5.6 million patients fall in this age bracket. With the baby-boom generation reaching around 65 years of age, this number is expected to reach 14 million, worsening the situation over the forecast period. By 2050, a new case of the disease is expected to develop every 33 seconds.
The major risk factor for most of the respiratory diseases is smoking. In 2016, more than 15 of every 100 US adults aged 18 years or older smoked cigarettes as per the estimates of Centre for Disease Control and Prevention (CDC). The cases of COPD is likely to increase in the US owing to higher smoking prevalence and aging populations in the country. Furthermore, as per the estimates of American Academy of Allergy, Asthma & Immunology, in 2016, around 8.3% of children in the United States had asthma. Asthma is the most common chronic disease in children.
Competitive Landscape The global Plasma Fractionation market is moderately competitive and consists of a number of major players. Companies like Bio Products Laboratory, Biotest AG, China Biologic Products, CSL Behring, Grifols S.A., Takeda Pharmaceutical Company Ltd, Kedrion S.p.A, Octapharma, Shanghai RAAS Blood Products, among others, hold the substantial market share in the market.
Reasons to Purchase this report: - The market estimate (ME) sheet in Excel format - 3 months of analyst support
Our reports have been used by over 10K customers, including:
The global interventional radiology market is projected to register a CAGR of 6.47% during the forecast period, with a revenue of USD 21,261.62 million in 2020 and expected to reach USD 31,262.67 million by 2026 The COVID-19 outbreak showed the impact on the interventional radiology market, as hospital and healthcare services were...
The apheresis market was valued at approximately USD 1,639 million in 2020, and it is expected to witness a revenue of USD 2580 million in 2026, with a CAGR of 7.85% over the forecast period, 2021-2026. The apheresis market is expected to be positively impacted during the COVID-19 pandemic owing to the extensive application of plasma...
The global amniotic products market is projected to reach USD 1.0 billion by 2026 from USD 0.7 billion in 2021, at a CAGR of 8.2% during the forecast period. The growth in this market can be attributed to the growth in the target patient population, rising incidence of burn injuries, awareness programs for wound care treatment and management,...
The healthcare analytical testing services market is projected to reach USD 9.8 billion by 2026 from USD 5.6 billion in 2021, at a CAGR of 11.9%. Growth in the market is driven by the rising trend of outsourcing of analytical testing by pharmaceutical companies and medical device companies, an increasing number of clinical trials, and the...
The Bioanalytical Testing Services Market was estimated to be USD 2,573.86 in 2020 and is projected to reach USD 5,021.83 million by 2026 at a CAGR of 11.59%. Bioanalytical technologies have played a critical role in the mitigation of the COVID-19 pandemic and will continue to be foundational in the prevention of the subsequent waves...
Interventional Cardiology Devices Market was valued at USD 13.11 billion in 2020, and is projected to reach a value of USD 20.07 billion by 2026, is expected to grow annually by 7.48% CAGR 2021-2026. The Interventional Cardiology Devices market is anticipated to have significantly impacted by the outbreak of the COVID-19 pandemic...
Real-world data and real-world evidence are used to monitor the post-market safety and adverse events of drugs.The monitoring of this data assists in making regulatory decisions. The healthcare community is using RWE and RWD to support coverage decisions and to develop guidelines and decision support tools for use in clinical practice. The...
The global Micropump market is expected to reach US$ 5,172.86 million in 2028 from as estimated value of US$ 1,553.01 million in 2021. The market is likely to grow with a CAGR of 18.8% from 2021-2028. The growth of the market is due to increasing demand for micropumps in medical device industry, and improved accuracy compared to traditional...
The patient monitoring systems market registered a market size of USD 26,198 million in 2020, and it is expected to reach 34,310 million by 2026, registering a CAGR of 8.87% during the forecast period. The growth of the patient monitoring market is attributed to the rising burden of chronic diseases due to lifestyle changes, growth in the...
The artificial intelligence in healthcare market is projected to grow from USD 6.9 billion in 2021 to USD 67.4 billion by 2027; it is expected to grow at a CAGR of 46.2%from 2021 to 2027. Many companies are developing software solutions for various healthcare applications; this is the key factor complementing the growth of the software...
Health Provider Density
Medical Technology Density
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.